Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: a retrospective study
This study investigated thyroid dysfunction with immune checkpoint inhibitors (ICIs) in terms of proportions affected, risk factors, thyroid sequelae, and overall survival (OS). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2024 Category: Cancer & Oncology Authors: Oliver John Kennedy, Nadia Ali, Rebecca Lee, Phillip Monaghan, Safwaan Adam, Tim Cooksley, Paul Lorigan Tags: Original Research Source Type: research
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
This study aimed to (1) confirm efficacy of CBP501/cisplatin/nivolumab for metast atic PDAC observed in a previous phase 1 study, (2) identify combinations that yield 35% 3-month progression-free survival rate (3MPFS) and (3) define the contribution of CBP501 to the effects of combination therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2024 Category: Cancer & Oncology Authors: T. Enzler, A. Nguyen, J. Misleh, V.J. Cline, M. Johns, N. Shumway, S. Paulson, R. Siegel, T. Larson, W. Messersmith, D. Richards, J. Chaves, E. Pierce, M. Zalupski, V. Sahai, D. Orr, S.A. Ruste, A. Haun, T. Kawabe Tags: Original Research Source Type: research
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – a real-world database study in Japan: The CReGYT-01 EGFR study
To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutation. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2024 Category: Cancer & Oncology Authors: Shinya Katsumata, Mototsugu Shimokawa, Akira Hamada, Naoki Haratake, Kotaro Nomura, Kosuke Fujino, Mao Yoshikawa, Ken Suzawa, Kazuhiko Shien, Kenichi Suda, Shuta Ohara, Shota Fukuda, Fumihiko Kinoshita, Kazuki Hayasaka, Hirotsugu Notsuda, Shinkichi Takamo Tags: Original Research Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - February 20, 2024 Category: Cancer & Oncology Source Type: research
Corrigendum to “Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer” [Eur J Cancer 199 (2024) 113572]
The authors regret that the code used to produce the dataset used for analysis included an error that duplicated thousands of cases. This shrunk the confidence intervals and inflated the statistical precision. The results of the paper did not change after the correction of this error but two interaction models were not better than those without and thus three figures were remade and all tables were updated with the correct number of cases and corrected odds ratios and confidence intervals. Figs. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Erik Osterman, Elisavet Syriopoulou, Anna Martling, Therese M.-L. Andersson, Caroline Nordenvall Tags: Corrigendum Source Type: research
Equal censoring but still informative: When the reasons for censoring differ between treatment arms
In randomized controlled trials, informative censoring has been described as a potential bias, mainly affecting time-to-event composite endpoints, like progression-free survival (PFS). It is usually suspected in the presence of unequal attrition rates between arms. Early censoring occurs for different reasons: patients may withdraw from a trial because of toxicity, or because of disappointment with their allocation arm. If censoring is more frequent in one arm due to increased toxicity, this removes the frailest individuals and introduces a bias favoring this arm. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 17, 2024 Category: Cancer & Oncology Authors: Timoth ée Olivier, Vinay Prasad Tags: Current perspective Source Type: research
Equal Censoring But Still Informative: When The Reasons For Censoring Differ Between Treatment Arms.
In randomized controlled trials, informative censoring has been described as a potential bias, mainly affecting time-to-event composite endpoints, like progression-free survival (PFS). It is usually suspected in the presence of unequal attrition rates between arms. Early censoring occurs for different reasons: patients may withdraw from a trial because of toxicity, or because of disappointment with their allocation arm. If censoring is more prevalent in one arm because of an excess in toxicity, removing the frailest individuals, a bias is introduced favoring this arm. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 17, 2024 Category: Cancer & Oncology Authors: Timoth ée Olivier, Vinay Prasad Tags: Current Perspective Source Type: research
EORTC QLQ-C30 normative data for the United Kingdom: Results of a cross-sectional survey of the general population
The cancer-specific health-related quality of life (HRQoL) questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC), the EORTC QLQ-C30, is a frequently applied questionnaire to assess cancer patients ’ self-reported health used as part of research and clinical practice. Normative data obtained from the general population can facilitate the interpretation of these data. Despite its frequent application, no detailed EORTC QLQ-C30 normative data have yet been published for the United Kingdom (UK) . (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Teresa Young, Galina Velikova, Gregor Liegl, Matthias Rose, Sandra Nolte, on behalf of the EORTC Quality of Life Group Tags: Original Research Source Type: research
Gemcitabine and nab-Paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial
The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line treatment of metastatic ductal adenocarcinoma of the pancreas (mPDAC). Afatinib, an oral second-generation pan ErbB family tyrosine kinase inhibitor, has shown promising pre-clinical signs in the treatment of pancreatic cancer. The aim of this phase 1b trial was to determine the maximum tolerated dose (MTD) of afatinib in combination with gemcitabine/nab-paclitaxel in patients with mPDAC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Danmei Zhang, C. Benedikt Westphalen, Michael Quante, Dirk T. Waldschmidt, Swantje Held, Fabian K ütting, Klara Dorman, Kathrin Heinrich, Lena Weiss, Myrto Boukovala, Michael Haas, Stefan Boeck, Volker Heinemann, Victoria Probst Tags: Original Research Source Type: research
Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries
We describe the characteristics, treatment patterns and clinical outcomes for patients with newly diagnosed multiple myeloma (NDMM) over 2010 –2018. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Niels Abildgaard, Pekka Anttila, Anders Waage, Katrine Hass Rubin, Sigurd Ørstavik, Nawal Bent-Ennakhil, François Gavini, Yuanjun Ma, Jonatan Freilich, Markus Hansson Tags: Original Research Source Type: research
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS
This study aimed to explore the impact of molecular profiling within the prospective precision cancer medicine trial MAPPYACTS (NCT02613962) on subsequent early phase trial recruitment and treatment by matched targeted therapies in this population. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Jordane CHAIX, Gudrun SCHLEIERMACHER, Nad ège CORRADINI, Nicolas ANDRE, Estelle THEBAUD, Marion GAMBART, Anne-Sophie DEFACHELLES, Natacha ENTZ-WERLE, Pascal CHASTAGNER, Émilie DE CARLI, Stéphane DUCASSOU, Judith LANDMAN-PARKER, Tiphaine ADAM-DE-BEAUMAI Tags: Original Research Source Type: research
Sotorasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Compassionate Use Program in Germany
Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 13, 2024 Category: Cancer & Oncology Authors: Jan A. Stratmann, Friederike C. Althoff, Paula Doebel, Jacqueline Rauh, Arne Trummer, Ali Nuri H ünerlitürkoglu, Nikolaj Frost, Hüsameddin Yildirim, Petros Christopoulos, Oswald Burkhard, Christian Meyer zum Büschenfelde, Aaron Becker von Rose, Jürge Tags: Original Research Source Type: research
Molecular Tumor Boards: on the evolution of species
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Patrizio Giacomini, Gennaro Ciliberto Tags: Letter to the Editor Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - February 10, 2024 Category: Cancer & Oncology Source Type: research
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer
We have previously found that HER2 expression is dynamic, and can change from the primary breast tumor to matched recurrences. With this work, we aimed to assess the dynamics of HER2 during neoadjuvant treatment.(NAT). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 10, 2024 Category: Cancer & Oncology Authors: Paolo Tarantino, Ogheneochuko Ajari, Noah Graham, Julie Vincuilla, Tonia Parker, Melissa E. Hughes, Nabihah Tayob, Ana C. Garrido-Castro, Stefania Morganti, Tari A. King, Elizabeth A. Mittendorf, Giuseppe Curigliano, Nancy U. Lin, Sara M. Tolaney Tags: Original research Source Type: research
